Sanjay Surana

Managing Director

The generics drug market in India is experiencing rapid growth, driven by rising healthcare costs, government support for affordable medication, and increasing consumer awareness of generics' efficacy and cost-effectiveness. The branded generics sector, in particu­lar, is experiencing substantial growth globally, with India emerging as a key player. The country's ability to provide high-quality products at competitive prices meets multina­tional standards, fueling global demand. The Indian brand­ed generics sector is expanding significantly, with demand growing rapidly worldwide.

Maxwell Life Science, founded by Sanjay Surana, is well-positioned in the thriving generics market, leveraging his 32 years of extensive experience in the pharmaceutical industry. Having worked across various roles, from shop floor chemist to technical director, Sanjay Surana has built a strong foundation for the company since its inception in 2004. The firm excels in manufacturing a wide range of tablets, capsules, liquid orals & skin ointments, specializing in categories such as antibiotics, multivitamins, antidiabetic, cardiovascular, and antifungal treatments. The company operates in over 120 molecules and 400 formulations, catering to markets across Africa, Latin America, Southeast Asia, and India, and has also successfully participated in government tenders in states like Rajasthan, West Bengal, Bihar, Tamil Nadu, and Maharashtra.

Maxwell Life Science stands out in the generics market due to its robust in-house systems and technical expertise. With a comprehensive in-house system, the firm efficiently handles production, packaging, logistics, and marketing, ensuring fast decision-making and problem-solving without breaking any regulations or standard procedures. Unlike larger multinational companies that often face bureaucratic delays, Maxwell's technical leadership allows for immediate action, reducing costs and time, while enhancing productivity. Additionally, the company actively seeks to expand its product portfolio by targeting new molecules and categories, enhancing its presence in government tenders and export markets.

Maxwell Life Science ensures strict compliance with WHO standards by maintaining robust Standard Operating Procedures (SOPs) and continuously upgrading its processes. A dedicated, qualified trainer provides regular staff training to ensure adherence to the highest quality benchmarks. Each product undergoes thorough quality control measures, from the selection of active pharmaceutical ingredients (APIs) to the use of the latest molecules and excipients. The company prioritizes the use of top-tier preservatives, binding agents, and disintegrants, ensuring superior dissolution and efficacy. Its commitment to continuous research and innovation enhances product quality, delivering optimal therapeutic results while maintaining competitive pricing.

Maxwell Life Science ensures effective distribution and timely product delivery across global markets by strategically managing its logistics. For exports, the company works closely with shipping agents and secures vessel schedules in advance, allowing for seamless production planning and on-time dispatch of container-load orders. In domestic markets, particularly with government tenders, Maxwell partners with established logistics providers. These partners use centralized depots within each state, ensuring efficient distribution to government depots. Maxwell's dedicated dispatch team, trained in the specific requirements of each region, streamlines processes, managing shipping documentation and communication to ensure smooth, timely deliveries. This well-coordinated system minimizes logistical challenges across all markets.

Leading Innovation in Manufacturing and Global Distribution Excellence

Maxwell Life Science prioritizes market research to identify trends and consumer needs during the development of new pharmaceutical formulations. The company closely monitors emerging lifestyles, particularly among younger generations in India, and adapts its product portfolio accordingly. Focused on growing categories such as antidiabetic, antihypertensive, anticardiac, and vitamin supplements like Vitamin D3, Maxwell actively expands its offerings to meet future demand. Additionally, recognizing the rising need for treatments addressing lifestyle-related issues such as decreased potency and skin infections, the company is developing formulations to address these concerns. By staying ahead of market trends and understanding consumer behavior, Maxwell ensures its product portfolio is aligned with the evolving healthcare landscape.

The company consistently leverages cutting-edge technology and innovation to enhance its manufacturing capabilities and meet evolving market demands. Over the past 20 years, the company has continuously upgraded its operations, recognizing that staying competitive requires ongoing innovation. By customizing machinery for automation and higher output, Maxwell maximizes efficiency within its existing facilities. The company collaborates with machine manufacturers to implement advanced systems that ensure precise quality control, such as weight variation monitoring, metal detection, and powder cleaning systems. Additionally, it prioritizes staff development, providing training and appointing skilled operators capable of handling advanced equipment, ensuring superior product quality, and maintaining a competitive edge in the industry.

Looking ahead, Maxwell Life Science is committed to leveraging its strengths in manufacturing and quality to shape its future roadmap. With a highly qualified team, the firm plans to establish new plants that enhance production capacity and incorporate advanced systems. Currently certified by WHO and following GMP standards, it aims to pursue higher-level certifications, including UK MHRA, to expand its international presence. Additionally, the firm is launching a mobile app for retailers, streamlining the ordering process and cutting marketing costs. This innovation will enable direct orders, faster delivery, and better margins for retailers, strengthening Maxwell’s market position and customer engagement.

"I have a broad vision for our company, aiming to establish multiple manufacturing facilities. To support this growth, I am nurturing young talent, and providing excellent training to fresh graduates. This prepares our skilled staff for smooth transitions between plants as we expand. I actively seek new talent and identify dedicated individuals eager for personal development, and I'm proud to see that my children are also joining this field, continuing our legacy in the industry", concludes Sanjay Surana, Managing Director, Maxwell Life Science.